Kathleen Montpetit1, Telma Palomo2, Francis H Glorieux3, François Fassier3, Frank Rauch3. 1. Shriners Hospital for Children, Montreal, QC, Canada. Electronic address: kmontpetit@shrinenet.org. 2. Shriners Hospital for Children, Montreal, QC, Canada. 3. Shriners Hospital for Children, Montreal, QC, Canada; McGill University, Montreal, QC, Canada.
Abstract
OBJECTIVE: To determine the functional outcomes associated with long-term multidisciplinary treatment, intravenous bisphosphonate treatment, orthopedic surgery, and rehabilitation in children with severe osteogenesis imperfecta (OI) (diagnosed clinically as OI types III or IV). DESIGN: Retrospective study where outcomes were measured prospectively. SETTING: Pediatric orthopedic hospital. PARTICIPANTS: Adolescents (N=41; age range, 15-21y) with severe OI (OI type III: n=17; OI type IV: n=24) who had started therapy before the age of 6 years, had received treatment for at least 10 years, and had achieved final height. INTERVENTIONS: Intravenous bisphosphonate treatment, orthopedic surgery, and rehabilitation. MAIN OUTCOME MEASURE: Pediatric Evaluation of Disability Inventory. RESULTS: At the time of the last available follow-up examination, none of the individuals diagnosed with OI type III (most severely affected group) was able to ambulate without ambulation aids, whereas 20 (83%) patients with OI type IV were able to ambulate without ambulation aids. Regarding self-care, we specifically assessed 8 skills that we deemed essential for living independently (grooming; dressing; toileting; bed, chair, toilet, tub, and car transfers). Only 6 (35%) of the youths with OI type III were able to complete all 8 items, whereas 23 (96%) individuals with OI type IV managed to perform all tasks. Teens with OI type III often needed assistance for the transfer to toilet, tub, and car and for personal hygiene and clothing management associated with toileting, usually because of limitations in upper-extremity function. CONCLUSIONS: These observations suggest that further improvements in the functional status of the most severely affected children with OI are contingent on advances in the clinical management of upper-extremity issues.
OBJECTIVE: To determine the functional outcomes associated with long-term multidisciplinary treatment, intravenous bisphosphonate treatment, orthopedic surgery, and rehabilitation in children with severe osteogenesis imperfecta (OI) (diagnosed clinically as OI types III or IV). DESIGN: Retrospective study where outcomes were measured prospectively. SETTING: Pediatric orthopedic hospital. PARTICIPANTS: Adolescents (N=41; age range, 15-21y) with severe OI (OI type III: n=17; OI type IV: n=24) who had started therapy before the age of 6 years, had received treatment for at least 10 years, and had achieved final height. INTERVENTIONS: Intravenous bisphosphonate treatment, orthopedic surgery, and rehabilitation. MAIN OUTCOME MEASURE: Pediatric Evaluation of Disability Inventory. RESULTS: At the time of the last available follow-up examination, none of the individuals diagnosed with OI type III (most severely affected group) was able to ambulate without ambulation aids, whereas 20 (83%) patients with OI type IV were able to ambulate without ambulation aids. Regarding self-care, we specifically assessed 8 skills that we deemed essential for living independently (grooming; dressing; toileting; bed, chair, toilet, tub, and car transfers). Only 6 (35%) of the youths with OI type III were able to complete all 8 items, whereas 23 (96%) individuals with OI type IV managed to perform all tasks. Teens with OI type III often needed assistance for the transfer to toilet, tub, and car and for personal hygiene and clothing management associated with toileting, usually because of limitations in upper-extremity function. CONCLUSIONS: These observations suggest that further improvements in the functional status of the most severely affected children with OI are contingent on advances in the clinical management of upper-extremity issues.
Authors: Keren Machol; Trevor D Hadley; Jake Schmidt; David Cuthbertson; Henri Traboulsi; Rodrigo C Silva; Chloe Citron; Sobiah Khan; Kate Citron; Erin Carter; Kenneth Brookler; Jay R Shapiro; Robert D Steiner; Peter H Byers; Francis H Glorieux; Michaela Durigova; Peter Smith; Michael B Bober; Vernon R Sutton; Brendan H Lee; Sandesh C S Nagamani; Cathleen Raggio Journal: Am J Med Genet A Date: 2019-12-26 Impact factor: 2.802
Authors: Christopher S Constantino; Joseph J Krzak; Alissa V Fial; Karen M Kruger; Jacob R Rammer; Katarina Radmanovic; Peter A Smith; Gerald F Harris Journal: JBMR Plus Date: 2019-10-18
Authors: Karen M Kruger; Angela Caudill; Mercedes Rodriguez Celin; Sandesh C S Nagamani; Jay R Shapiro; Robert D Steiner; Michael B Bober; Tracy Hart; David Cuthbertson; Jeff Krischer; Peter H Byers; Michaela Durigova; Francis H Glorieux; Frank Rauch; V Reid Sutton; Brendan Lee; Eric T Rush; Peter A Smith; Gerald F Harris Journal: Genet Med Date: 2019-03-28 Impact factor: 8.822